Previous 10 | Next 10 |
PTC Therapeutics (PTCT) and exclusive licensee Genentech, a unit of Roche (RHHBY), announce two-year data from Part 1 of the pivotal Phase 2/3 FIREFISH study evaluating Evrysdi (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy ((SMA)). Infants treated rece...
Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones - Patients in Part 1 of the FIREFISH study demonstrated gains in motor milestones between months 12 and 24 - - Strong Evrysdi...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadA relatively light earnings and conference calendar in the week ahead doesn't mean a break for investors. The U.S. airlin...
PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit PR Newswire SOUTH PLAINFIELD, N.J., Sept. 24, 2020 SOUTH PLAINFIELD, N.J. , Sept. 24, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management w...
SOUTH PLAINFIELD, N.J. , Sept. 9, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new program that provides genetic testing and counseling for people who may have a neurotransmitter disorder, such as aromatic L-amino acid decarboxylase (AADC) deficiency....
SOUTH PLAINFIELD, N.J. , Sept. 8, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the winners of its sixth annual STRIVE Awards grant program for Duchenne muscular dystrophy. This year's winning initiatives, spanning across four continents, include an onlin...
SOUTH PLAINFIELD, N.J. , Sept. 3, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Cantor Virtual Global Healthcare Conference on Thursday, September 17 th at 9:20 a.m. ET . The presentation will b...
Investment thesis Volume transactions by "institutions" managing multi-billion-dollar portfolios force equity markets into two behaviors: (1) Small regularly-repeatable transactions between individual investors which are system-automated at near-zero cost of handling and (2) giant-volume irr...
PTC Therapeutics (NASDAQ: PTCT ) has received a $20M milestone payment from Roche ( OTCQX:RHHBY ) , triggered by the first commercial sale of Evrysdi (risdiplam) in the U.S., under its License and Collaboration Agreement. More news on: PTC Therapeutics, Inc., Roche Holding A...
SOUTH PLAINFIELD, N.J. , Aug. 26, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company achieved a $20 million milestone payment from Roche under its License and Collaboration Agreement. The milestone payment was triggered by the first comme...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....